Expert Opinion on Investigational Drugs (EOID)

Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Opinion on Investigational Drugs address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies. Drug Evaluations reviewing the clinical and pharmacological data on a particular drug. Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials. Please note that we do not consider case report or case series articles.

Expert Opinion on Investigational Drugs (EOID) is :-

• International, Peer-Reviewed, Open Access, Refereed, the needs of scientists, managers, decision-makers, pharmaceutical industry, clinical development, providing expert opinion, the scope for future development , Online or Print , Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1354-3784, E-ISSN: 1744-7658, Established: 1992, Impact Factor: 4.9
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE